Search - tctmd.com

Displaying 1 - 20 of 74

Sort: Relevancy | Date

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Presenter: Michael Bloch

October 29, 2024

Presentation TCT 2024

What Evaluation is Required for Patient Selection for RDN?

Presenter: Naomi Fisher

October 29, 2024

Presentation TCT 2024

What’s Next - Going into 2025

Presenter: Vijay Iyer

October 28, 2024

Presentation TCT 2024

Building Real-world Clinical Evidence: Global Paradise System (GPS) Registry

Presenter: Naomi Fisher

October 28, 2024

Presentation TCT 2024

Getting Started: Establishing a Patient Care Pathway

Presenter: Matheen Khuddus

October 28, 2024

Presentation TCT 2024

Science of Ultrasound RDN

Presenter: Michael Joner

October 28, 2024

Presentation TCT 2024

The New CKM Scientific Statement: Expanding the Cardiometabolic Focus and Including the Kidney

Presenter: Chiadi Ndumele

October 28, 2024

Presentation TCT 2024

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

Presenter: Manasa Jasti

October 28, 2024

Presentation TCT 2024

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

Presenter: Roland Schmieder

October 28, 2024

Presentation TCT 2024

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

Presenter: Abraham Tzafriri

October 28, 2024

Advertisement

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

What Evaluation is Required for Patient Selection for RDN?

What’s Next - Going into 2025

Building Real-world Clinical Evidence: Global Paradise System (GPS) Registry

Getting Started: Establishing a Patient Care Pathway

Science of Ultrasound RDN

The New CKM Scientific Statement: Expanding the Cardiometabolic Focus and Including the Kidney

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content